Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125973711 | 12597371 | 1 | I | 20100308 | 20140101 | 20160727 | 20160727 | EXP | US-ROCHE-1329221 | ROCHE | 59.00 | YR | F | Y | 50.60000 | KG | 20160727 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125973711 | 12597371 | 1 | PS | Vismodegib | VISMODEGIB | 1 | Oral | CYCLE 21 DAYS, CYCLES 1-4. LAST DOSE PRIOR TO EVENT OF ANOREXIA: 25/APR/2010?LAST DOSE RECEIVED ON 0 | U | 203388 | 3150 | MG | CAPSULE | ||||||
| 125973711 | 12597371 | 2 | SS | Vismodegib | VISMODEGIB | 1 | Oral | COURSE 2 | U | 203388 | 3150 | MG | |||||||
| 125973711 | 12597371 | 3 | SS | Vismodegib | VISMODEGIB | 1 | Oral | COURSE 3 | U | 203388 | 3000 | MG | |||||||
| 125973711 | 12597371 | 4 | SS | Vismodegib | VISMODEGIB | 1 | Oral | COURSE 4 | U | 203388 | 3450 | MG | |||||||
| 125973711 | 12597371 | 5 | SS | Vismodegib | VISMODEGIB | 1 | Oral | COURSE 5 | U | 203388 | 3450 | MG | |||||||
| 125973711 | 12597371 | 6 | SS | Vismodegib | VISMODEGIB | 1 | Oral | COURSE 6 | U | 203388 | 3150 | MG | |||||||
| 125973711 | 12597371 | 7 | SS | Vismodegib | VISMODEGIB | 1 | Oral | COURSE 7 | U | 203388 | 3150 | MG | |||||||
| 125973711 | 12597371 | 8 | SS | Vismodegib | VISMODEGIB | 1 | Oral | COURSE 8 | U | 203388 | 3300 | MG | |||||||
| 125973711 | 12597371 | 9 | SS | Vismodegib | VISMODEGIB | 1 | Oral | COURSE 9 | U | 203388 | 3150 | MG | |||||||
| 125973711 | 12597371 | 10 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | DOSE:100 MG/M2/DAY IV OVER 2 HRS ON DAYS 1-3 | U | 0 | |||||||||
| 125973711 | 12597371 | 11 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | DOSE: OVER 2 HRS ON DAY 1 CYCLES 5 | U | 0 | 75 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125973711 | 12597371 | 1 | Small cell lung cancer |
| 125973711 | 12597371 | 10 | Small cell lung cancer |
| 125973711 | 12597371 | 11 | Small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125973711 | 12597371 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125973711 | 12597371 | Decreased appetite | |
| 125973711 | 12597371 | Fatigue | |
| 125973711 | 12597371 | Nausea | |
| 125973711 | 12597371 | Neutrophil count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125973711 | 12597371 | 1 | 20100222 | 0 | ||
| 125973711 | 12597371 | 2 | 20100315 | 0 | ||
| 125973711 | 12597371 | 3 | 20100405 | 0 | ||
| 125973711 | 12597371 | 4 | 20100426 | 0 | ||
| 125973711 | 12597371 | 5 | 20100519 | 0 | ||
| 125973711 | 12597371 | 6 | 20100609 | 0 | ||
| 125973711 | 12597371 | 7 | 20100630 | 0 | ||
| 125973711 | 12597371 | 8 | 20100721 | 0 | ||
| 125973711 | 12597371 | 9 | 20100812 | 0 | ||
| 125973711 | 12597371 | 10 | 20100222 | 0 | ||
| 125973711 | 12597371 | 11 | 20100222 | 0 |